Teva, the Israeli drugmaker, plans to raise prices on a string of medicines in the US to help repair its ailing business — even as analysts warn that the move risks provoking a backlash among customers and politicians.
Like other generic drugmakers, Teva has signed multi-medicine contracts with many customers where it sells some products at break-even or a loss and tries to recoup the difference on more profitable lines.
However, Kåre Schultz, Teva’s recently appointed chief executive, has told investors he wants to either raise the price of some of these “non-economical” drugs or stop manufacturing them altogether.
More: http://on.ft.com/2oIIG8z